Inhibitory effect of YC-1, 3-(5′-hydroxymethyl-2′-furyl)-1- benzylindazole, on experimental choroidal neovascularization in rat

Ophthalmic Research

Volumn 40, Issue 1, 2007, Pages 35-40

  Song, Su Jeong ^a,b   Chung, Hum ^a   Yu, Hyeong Gon ^a,c  

^a Seoul National University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Choroidal neovascularization; Fluorescein leakage; Hypoxia inducible factor 1; YC 1, 3 (5 hydroxymethyl 2 furyl) 1 benzylindazole

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; DIMETHYL SULFOXIDE; FLUORESCEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG INHIBITION; FEMALE; IMMUNOFLUORESCENCE TEST; LASER COAGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STAINING; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FLUORESCENT ANTIBODY TECHNIQUE; FUNDUS OCULI; HYPOXIA-INDUCIBLE FACTOR 1; INDAZOLES; LASER COAGULATION; RATS; RATS, INBRED BN; STAINING AND LABELING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37349113898     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111157     Document Type: Article

References (29)

1. Hyman LG, Lilienfeld AM, Ferris FL 3rd, Fine SL: Senile macular degeneration: a case-control study. Am J Epidemiol 1983;118:213-227.
2. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-1114.
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report 1. Arch Ophthalmol 1999;117:1329-1345.
4. Culla T, Criswell MH, Danis RP, Hill TE: Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001;119:399-404.
5. Krzystolik MG, Afshari MA, Adamis AP, et al: Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-346.
6. Kwak N, Okamoto N, Wood JM, Campochiaro PA: VEGF is a major stimulator in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000;41:3158-3164.
7. Pan SL, Guh JH, Peng CY, et al: YC-1 [3-(5′-hydroxymethyl-2′- furyl)-1-benzylindazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models. J Pharmacol Exp Ther 2005;314:35-42.
8. Yeo E, Chun Y, Kim J, et al: YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-525.
9. Chun Y, Yeo E, Choi E, et al: Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3N cells. Biochem Pharmacol 2001;61:947-954.
10. Semenza GL: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474-1480.
11. Kang K, Yu HG, Seo J, et al: Expression of hypoxia-inducible factor-1α (HIF-1α) in the experimental model of choroidal neovascularization. J Korean Ophthalmol Soc 2004;45:1541-1546.
12. Lopez PF, Sippy B, Lambert H, Thach A, Hinton D: Transdifferentiated RPE cells and immunoreactivity in surgically excised ARND-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855-868.
13. Grunwald JE, Metelitsina TI, Dupont J, et al: Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005;46:1033-1038.
14. Grunwald JE, Hariprasad SM, Dupont J, et al: Foveolar choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci 1998;39:385-390.
15. Vinores SA, Xiao WH, Aslam S, et al: Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol 2006;206:749-758.
16. Hsu H, Juan S, Ho P, et al: YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway. Biochem Pharmacol 2003;66:263-271.
17. Lukiw WJ, Ottlecz A, Lambrou G, et al: Coordinate activation of HIF-1 and NF-κB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest Ophthalmol Vis Sci 2003;44:4163-4170.
18. Guerrin M, Moukadiri H, Chollet P, et al: Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 1995;164:385-394.
19. Ko FN, Wu CC, Kuo SC, Lee FY, et al: YC-1, a novel activator of platelet guanylate cyclase. Blood 1994;84:4226-4233.
20. Yu SM, Cheng ZJ, Guh JH, et al: Mechanism of antiproliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells. Biochem J 1995;306:787-792.
21. Friebe A, Mullershausen F, Smolenski A, et al: YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 1998;54:962-967.
22. Galle J, Zabel U, Hubner U, et al: Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 1999;127:195-203.
23. Koglin M, Stasch JP, Behrends S: BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase. Biochem Biophys Res Commun 2002;292:1057-1062.
24. Sun HL, Liu YN, Huang YT, et al: YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxia. Oncogene 2007;26:3941-3951.
25. Kim HL, Yeo EJ, Chun YS, Park JW: A domain responsible for HIF-1α degradation by YC-1, a novel anticancer agent. Int J Oncol 2006;29:255-260.
26. Lum JJ, Bui T, Gruber M, Gordan JD, et al: The transcription factor HIF-1α plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 2007;21:1037-1049.
27. Yeo EJ, Chun YS, Cho YS, et al: YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res 2006;66:6345-6352.
28. Floyd ZE, Kilroy G, Wu X, Gimble JM: Effects of prolyl hydroxylase inhibitors on adipogenesis and hypoxia inducible factor 1α levels under normoxic conditions. J Cell Biochem 2007, E-pub ahead of print.
29. Zhao Q, Du J, Gu H, et al: Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas 2007;34:242-247.